1. Home
  2. LWAY vs LCTX Comparison

LWAY vs LCTX Comparison

Compare LWAY & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LWAY

Lifeway Foods Inc.

HOLD

Current Price

$22.11

Market Cap

347.2M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LWAY
LCTX
Founded
1986
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
347.2M
366.2M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
LWAY
LCTX
Price
$22.11
$1.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$35.00
$4.67
AVG Volume (30 Days)
49.7K
1.2M
Earning Date
03-13-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.74
N/A
Revenue
$204,069,000.00
$10,816,000.00
Revenue This Year
$15.23
$6.32
Revenue Next Year
$13.72
$124.49
P/E Ratio
$29.61
N/A
Revenue Growth
12.14
24.05
52 Week Low
$19.50
$0.37
52 Week High
$34.20
$2.09

Technical Indicators

Market Signals
Indicator
LWAY
LCTX
Relative Strength Index (RSI) 46.87 51.23
Support Level $21.25 $1.68
Resistance Level $22.50 $1.90
Average True Range (ATR) 0.64 0.11
MACD 0.06 0.01
Stochastic Oscillator 40.61 56.67

Price Performance

Historical Comparison
LWAY
LCTX

About LWAY Lifeway Foods Inc.

Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: